By conducting a systematic review on the current standard of biomarker
use in CVD, iCARE4CVD will describe how these biomarkers relate to
disease progression, the body’s response to CVD, and their use in current
standard practice.
This will allow us to define correlations between different biomarkers,
identify existing gaps, and enable us to model the entire spectrum of CVD
from early risk to advanced disease progression.
Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) and Breakthrough T1D under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.